KOREA ARLICO PHARM CO.,LTD. Q3 revenue KRW 53.1 billion, operating loss of KRW 0.8 billion
AI summary · Not investment advice
Alico Pharm sold KRW 53.1 billion worth in Q3 but lost KRW 0.8 billion from its main business, turning from profit to loss versus a year earlier.
Operating profit · 3 months
KRW -802.3 million
Key facts
- Revenue (3 months)
- KRW 53.1 billion
- Net income (3 months)
- KRW -1.1 billion
- Period
- Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
- Revenue (prior-year 3 months)
- KRW 52.2 billion
- Revenue (year to date)
- KRW 148.3 billion
- Operating profit (prior-year 3 months)
- KRW 4.0 million
- Operating profit (year to date)
- KRW -7.1 billion
- Net income (prior-year 3 months)
- KRW -553.8 million
- Net income (year to date)
- KRW -2.5 billion
Commentary
AI commentary · Not investment advice
What happened
Alico Pharm reported its separate-basis results for the third quarter of 2026. Sales for the latest 3 months were KRW 53.08 billion. That is 1.7% more than the same period a year earlier, and 13.3% more than the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the 3 months was a loss of KRW 802.3 million. A year earlier it was a profit of KRW 4.0 million, so it turned to a loss. Net income (final profit after taxes and other items) for the 3 months was a loss of KRW 1.14 billion. A year earlier it was a loss of KRW 553.8 million.
What changes for shareholders
For the year to date (January 1 to September 30), sales were KRW 148.26 billion. Operating profit was a loss of KRW 7.14 billion. Net income was a loss of KRW 2.45 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
K